ロード中...
A147 COMBINING INFLIXIMAB TROUGH LEVELS AND FECAL CALPROTECTIN LEVELS WITH CLINICAL DATA HAS THE POTENTIAL TO GUIDE CLINICAL DECISION-MAKING IN IMPROVING OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB.
BACKGROUND: Infliximab (IFX) induces and maintains remission in Crohn’s Disease (CD) and Ulcerative Colitis (UC). Secondary loss of response occurs in up to 45% of CD and 60% of UC patients on maintenance IFX. Studies are inconclusive on ideal IFX trough levels (ITLs) to prevent loss of response; re...
保存先:
| 出版年: | J Can Assoc Gastroenterol |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507628/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.148 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|